Agent Capital
company launched with technology developed at the University of Pennsylvania Medical School. Previously, Dr. Siciliano was the CEO and Co-Founder of Invisible Sentinel, Inc. a molecular diagnostic company that was acquired by bioMerieux, a global market leader for diagnostic testing, in February 2019. Dr. Siciliano was the inventor of Invisible Sentinel's proprietary platform technologies, veriFLOW and veriPRO, and led the company's business and R&D initiatives from the concept through acquisition.
Dr. Siciliano received a B.S. degree in Chemistry from Villanova University and shortly thereafter began his scientific career in the department of Microbiology at the University of Pennsylvania Medical School studying host-pathogens interactions. He then earned a Ph.D. in Immunology and Microbial Pathogenesis from Thomas Jefferson University where he studied antigen presentation. Nick also serves as the President of the Thomas Jefferson University College of Life Sciences Alumni Board. He holds multiple utility and design patents for diagnostic technologies and has published scientific manuscripts in the fields of bacteriology, virology, immunology, molecular biology, and cancer immunotherapy.
This person is not in any teams
This person is not in any offices
Agent Capital
Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Their investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. They make direct equity investments across all stages of development and types of financing rounds.